The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2017 | Striking results from the PACIFIC trial
The European Society for Medical Oncology (ESMO) conference allows experts in the field to share vital new results and data. Martin Reck, MD, PhD, from the Lung Clinic Grosshansdorf, Grosshansdorf, Germany explains to us why he was particularly excited by the findings of a Phase III clinical trial, PACIFIC (NCT02125461), which assessed the efficacy of the immunotherapeutic drug durvalumab in the treatment of stage III non-small cell lung cancer. This interview was recorded at ESMO 2017, held in Madrid, Spain.
